Troy Luster
Assistant Professor of Biology
Director, PSM Program in Biotechnology
Academic Profile
I have >15 years leading discovery teams at several biotechnology companies focused on developing new therapies for cancer. Prior to joining Brandeis, I had several adjunct roles at area universities teaching lecture- and laboratory-based courses in biotechnology.
Selected Publications
-
Lizotte PH, Hong RL, Luster TA, Cavanaugh ME, Taus LJ, Wang S, Dhaneshwar A, Mayman N, Yang A, Kulkarni A, Badalucco L, Fitzpatrick E, Kao HF, Kuraguchi M, Bittinger M, Kirschmeier PT, Gray NS, Barbie DA, Jänne PA. A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. (2018) Cancer Immunol Res. 6(12), 1511-1523.
-
Luster TA, Mukherjee I, Carrell JA, Cho YH, Gill J, Kelly L, Garcia A, Ward C, Oh L, Ullrich S, Migone TS, Humphreys R. Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo. (2012) PLOS One. 7(10), e47361.
-
He J, Yin Y, Luster TA, Watkins L, Thorpe PE. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. (2009) Clin Cancer Res. 15, 6871-6880.
-
Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. (2009) Mol Cancer Ther. 8, 292-302.
-
Luster TA, He J, Huang X, Maiti SN, Schroit AJ, de Groot PG, Thorpe PE. Plasma protein beta-2-glycoprotein-1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. (2006) J Biol Chem. 281, 29863-29871.